DOI QR코드

DOI QR Code

Association Between MDM2 Promoter SNP309 T/G Polymorphism and Liver Cancer Risk - a Meta-analysis

  • Ma, Hong-Bo (Department of Hepatobiliary and Pancreatic Surgery, Henan Tumor Hospital, the Affiliated Tumor Hospital of Zhengzhou University) ;
  • Huang, Tao (Department of Hepatobiliary and Pancreatic Surgery, Henan Tumor Hospital, the Affiliated Tumor Hospital of Zhengzhou University) ;
  • Han, Feng (Department of Hepatobiliary and Pancreatic Surgery, Henan Tumor Hospital, the Affiliated Tumor Hospital of Zhengzhou University) ;
  • Chen, Wei-Yu (Department of Hepatobiliary and Pancreatic Surgery, Henan Tumor Hospital, the Affiliated Tumor Hospital of Zhengzhou University)
  • Published : 2012.06.30

Abstract

Background: Many studies have investigated the association between the MDM2 promoter SNP309 T/G polymorphism and liver cancer risk, but inconsistencies make drawwing definitive conclusions difficult. Methods: We therefore searched main databases for articles relating MDM2 SNP309 T/G polymorphism to risk of liver cancer in humans and estimated summary odds ratio (OR) with 95% confidence intervals (95% CI) to assess the possible association in a meta-analysis. Results: The main analysis revealed no significant heterogeneity, and the pooled ORs of fixed-effects were all significant (for G versus T, OR = 1.59, 95% CI 1.42-1.78; for GG versus TT, OR = 2.45, 95% CI 1.93-3.12; for GT versus TT, OR = 1.70, 95% CI 1.38-2.09; for GG versus GT, OR = 1.49, 95% CI 1.24-1.79; for GG and GT versus TT, OR = 1.95, 95% CI 1.61-2.38; for GG versus TT and GT, OR = 1.73, 95% CI 1.46-2.07). Subgroup analyses by ethnicity and sensitivity analyses both showed associations to remain significant. Conclusion: The present meta-analysis of available data showed a significant association between the MDM2 SNP309 T/G polymorphism and liver cancer risk, the MDM2 SNP309 G allele contributing to increased risk in both Asians and Caucasians in a graded, dose-dependent fashion.

Keywords

Liver cancer;MDM2;polymorphism;risk factor;meta-analysis

References

  1. Akkiz H, Sumbul AT, Bayram S, et al (2010). MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population. Cancer Epidemiol, 34, 448-52. https://doi.org/10.1016/j.canep.2010.04.008
  2. Bridges JF, Joy SM, Gallego G, et al (2011). Needs for hepatocellular carcinoma control policy in the Asia-Pacific region. Asian Pac J Cancer Prev, 12, 2585-91.
  3. Chen WQ (2009). Estimation of cancer incidence and mortality in China in 2004-2005. Chin J Cancer, 31, 664-8.
  4. Cheok CF, Verma CS, Baselga J, et al (2011). Translating p53 into the clinic. Nat Rev Clin Oncol, 8, 25-37. https://doi.org/10.1038/nrclinonc.2010.174
  5. Cochran WG (1954). The combination of estimates from different experiments. Biometrics, 10, 101-29. https://doi.org/10.2307/3001666
  6. Deisenroth C, Zhang Y (2010). Ribosome biogenesis surveillance: probing the ribosomal protein-Mdm2-p53 pathway. Oncogene, 29, 4253-60. https://doi.org/10.1038/onc.2010.189
  7. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88. https://doi.org/10.1016/0197-2456(86)90046-2
  8. Dharel N, Kato N, Muroyama R, et al (2006). MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Clin Cancer Res, 12, 4867-71. https://doi.org/10.1158/1078-0432.CCR-06-0111
  9. Di Vuolo V, Buonaguro L, Izzo F, et al (2011). TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients. Infect Agent Cancer, 6, 13. https://doi.org/10.1186/1750-9378-6-13
  10. Ding C, Yu H, Qin H (2012). TP53 Codon 72 Polymorphism with Hepatocellular Carcinoma: a Metaanalysis. J Int Med Res, 40, 446-54. https://doi.org/10.1177/147323001204000206
  11. Dongiovanni P, Fracanzani AL, Cairo G, et al (2010). Iron-dependent regulation of MDM2 influences p53 activity and hepatic carcinogenesis. Am J Pathol, 176, 1006-17. https://doi.org/10.2353/ajpath.2010.090249
  12. Economopoulos KP, Sergentanis TN (2010). Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis. Breast Cancer Res Treat, 120, 211-6. https://doi.org/10.1007/s10549-009-0467-1
  13. Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34. https://doi.org/10.1136/bmj.315.7109.629
  14. El-Serag HB (2011). Hepatocellular carcinoma. N Engl J Med, 365, 1118-27. https://doi.org/10.1056/NEJMra1001683
  15. Embade N, Fernandez-Ramos D, Varela-Rey M, et al (2012). Murine double minute 2 regulates Hu antigen R stability in human liver and colon cancer through NEDDylation. Hepatology, 55, 1237-48. https://doi.org/10.1002/hep.24795
  16. Ezzikouri S, El Feydi AE, Afifi R, et al (2009). MDM2 SNP309T>G polymorphism and risk of hepatocellular carcinoma: a case-control analysis in a Moroccan population. Cancer Detect Prev, 32, 380-5. https://doi.org/10.1016/j.cdp.2009.01.003
  17. Ezzikouri S, Essaid El Feydi A, Afifi R, et al (2011). Impact of TP53 codon 72 and MDM2 promoter 309 allelic dosage in a Moroccan population with hepatocellular carcinoma. Int J Biol Markers, 26, 229-33.
  18. Fang F, Yu XJ, Yu L, et al (2011). MDM2 309 T/G polymorphism is associated with colorectal cancer risk especially in Asians: a meta-analysis. Med Oncol, 28, 981-5. https://doi.org/10.1007/s12032-010-9577-1
  19. Forner A, Llovet JM, Bruix J (2012). Hepatocellular carcinoma. Lancet, 379, 1245-55. https://doi.org/10.1016/S0140-6736(11)61347-0
  20. Gajjar M, Candeias MM, Malbert-Colas L, et al (2012). The p53 mRNA-Mdm2 interaction controls Mdm2 nuclear trafficking and is required for p53 activation following DNA damage. Cancer Cell, 21, 25-35. https://doi.org/10.1016/j.ccr.2011.11.016
  21. Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60. https://doi.org/10.1136/bmj.327.7414.557
  22. Hu Z, Jin G, Wang L, et al (2007). MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies. Cancer Epidemiol Biomark Prev, 16, 2717-23. https://doi.org/10.1158/1055-9965.EPI-07-0634
  23. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  24. Jung CR, Lim JH, Choi Y, et al (2010). Enigma negatively regulates p53 through MDM2 and promotes tumor cell survival in mice. J Clin Invest, 120, 4493-506. https://doi.org/10.1172/JCI42674
  25. Kimman M, Norman R, Jan S, et al (2012). The Burden of Cancer in Member Countries of the Association of Southeast Asian Nations (ASEAN). Asian Pac J Cancer Prev, 13, 411-20. https://doi.org/10.7314/APJCP.2012.13.2.411
  26. Lauria A, Tutone M, Ippolito M, et al (2010). Molecular modeling approaches in the discovery of new drugs for anti-cancer therapy: the investigation of p53-MDM2 interaction and its inhibition by small molecules. Curr Med Chem, 17, 3142-54. https://doi.org/10.2174/092986710792232021
  27. Leu JD, Lin IF, Sun YF, et al (2009). Association between MDM2-SNP309 and hepatocellular carcinoma in Taiwanese population. World J Gastroenterol, 15, 5592-7. https://doi.org/10.3748/wjg.15.5592
  28. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
  29. Muellerleile P, Mullen B (2006). Sufficiency and stability of evidence for public health interventions using cumulative meta-analysis. Am J Public Health, 96, 515-22. https://doi.org/10.2105/AJPH.2003.036343
  30. Stommel JM, Wahl GM (2005). A new twist in the feedback loop: stress-activated MDM2 destabilization is required for p53 activation. Cell Cycle, 4, 411-7. https://doi.org/10.4161/cc.4.3.1522
  31. Stroup DF, Berlin JA, Morton SC, et al (2000). Meta-analysis of observational studies in epidemiology. JAMA, 283, 2008. https://doi.org/10.1001/jama.283.15.2008
  32. Wang B, Huang G, Wang D, et al (2010). Null genotypes of GSTM1 and GSTT1 contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis. J Hepatol, 53, 508-18. https://doi.org/10.1016/j.jhep.2010.03.026
  33. Wang X, Zhang X, Qiu B, et al (2012). MDM2 SNP309T>G polymorphism increases susceptibility to hepatitis B virus-related hepatocellular carcinoma in a northeast Han Chinese population. Liver Int, 32, 1172-8. https://doi.org/10.1111/j.1478-3231.2012.02787.x
  34. Whibley C, Pharoah PD, Hollstein M (2009). p53 polymorphisms: cancer implications. Nat Rev Cancer, 9, 95-107. https://doi.org/10.1038/nrc2584
  35. Wiangnon S, Kamsa-Ard S, Suwanrungruang K, et al (2012). Trends in incidence of hepatocellular carcinoma, 1990 - 2009, Khon Kaen, Thailand. Asian Pac J Cancer Prev, 13, 1065-8. https://doi.org/10.7314/APJCP.2012.13.3.1065
  36. Wilkening S, Bermejo JL, Hemminki K (2007). MDM2 SNP309 and cancer risk: a combined analysis. Carcinogenesis, 28, 2262-7. https://doi.org/10.1093/carcin/bgm191
  37. Yoon YJ, Chang HY, Ahn SH, et al (2008). MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis, 29, 1192-6. https://doi.org/10.1093/carcin/bgn090
  38. Zhang MF, Zhang ZY, Fu J, et al (2009). Correlation between expression of p53, p21/WAF1, and MDM2 proteins and their prognostic significance in primary hepatocellular carcinoma. J Transl Med, 7, 110. https://doi.org/10.1186/1479-5876-7-110
  39. Zintzaras E, Lau J (2008). Synthesis of genetic association studies for pertinent gene-disease associations requires appropriate methodological and statistical approaches. J Clin Epidemiol, 61, 634-45. https://doi.org/10.1016/j.jclinepi.2007.12.011

Cited by

  1. Association of Type II Diabetes Mellitus with Hepatocellular Carcinoma Occurrence - a Case Control Study from Kathmandu Valley vol.13, pp.10, 2012, https://doi.org/10.7314/APJCP.2012.13.10.5097
  2. Association Between MDM2 SNP309 T>G and Risk of Gastric Cancer: A Meta-analysis vol.14, pp.3, 2013, https://doi.org/10.7314/APJCP.2013.14.3.1925
  3. Meta-analysis of associations between MDM2 SNP309 polymorphism and gastric cancer risk vol.2, pp.1, 2013, https://doi.org/10.3892/br.2013.181
  4. Human genetic variation and the risk of hepatocellular carcinoma development vol.7, pp.3, 2013, https://doi.org/10.1007/s12072-013-9463-y
  5. The MDM2 SNP309T>G Polymorphism Increases Bladder Cancer Risk among Caucasians: a Meta-analysis vol.15, pp.13, 2014, https://doi.org/10.7314/APJCP.2014.15.13.5277
  6. SCYL1BP1 has Tumor-suppressive Functions in Human Lung Squamous Carcinoma Cells by Regulating Degradation of MDM2 vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7467
  7. MDM2 SNP309T>G polymorphism and hepatocellular carcinoma risk: a meta-analysis vol.35, pp.5, 2014, https://doi.org/10.1007/s13277-013-1543-z
  8. MDM2 and TP53 Polymorphisms as Predictive Markers for Head and Neck Cancer in Northeast Indian Population: Effect of Gene-Gene and Gene-Environment Interactions vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.5767
  9. Genetic association of single nucleotide polymorphisms in P53 pathway with gastric cancer risk in a Chinese Han population vol.32, pp.1, 2015, https://doi.org/10.1007/s12032-014-0401-1
  10. Murine Double Minute 2 Gene Polymorphism Is an Independent Prognostic Factor for Patients with Renal Cell Carcinoma vol.34, pp.2, 2015, https://doi.org/10.1089/dna.2014.2653